Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022

Rhea-AI Summary

Agios Pharmaceuticals (NASDAQ: AGIO) will host a conference call and live webcast on November 3, 2022, at 8:00 a.m. ET to discuss its third quarter 2022 financial results and business updates. The webcast will be accessible on the company’s website in the Investors section and will be archived for later replay. Agios is recognized for its pioneering work in therapies for rare and genetically defined diseases, including a first-in-class pyruvate kinase activator for PK deficiency. The company continues to advance its clinical pipeline targeting various blood disorders.

Positive

• Agios markets a first-in-class pyruvate kinase activator for adults with PK deficiency.
• The company is advancing a robust clinical pipeline targeting diseases like sickle cell disease and thalassemia.

Negative

• None.

CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced the company will host a conference call and live webcast on Thursday, November 3, 2022, at 8:00 a.m. ET to report its third quarter 2022 financial results and other business highlights.

A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.

About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare and genetically defined diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with active and planned programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and an industry-leading research team with unmatched expertise in cellular metabolism and genetics. For more information, please visit the company’s website at www.agios.com.

Contacts

Investors:
Holly Manning, 617-844-6630
Senior Director, Investor Relations
Holly.Manning@agios.com

Media:
Jessica Rennekamp, 857-209-3286
Senior Director, Corporate Communications
Jessica.Rennekamp@agios.com

FAQ

When will Agios Pharmaceuticals report its third quarter 2022 financial results?

Agios Pharmaceuticals will report its third quarter 2022 financial results on November 3, 2022.

How can I access Agios Pharmaceuticals' conference call?

The conference call can be accessed via a live webcast on Agios Pharmaceuticals' website in the Investors section.

What is the significance of the PK activator marketed by Agios?

The PK activator is the first disease-modifying therapy for adults with pyruvate kinase deficiency, addressing a rare and debilitating condition.

What diseases is Agios Pharmaceuticals focusing on in its clinical pipeline?

Agios is focusing on alpha- and beta-thalassemia, sickle cell disease, and pediatric PK deficiency in its clinical pipeline.